[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640297":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":35,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":26,"enrollmentInfo":47,"targetDuration":26,"studyType":50,"phases":51,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":26},{"fullName":5,"class":6},"Guangdong Provincial Hospital of Traditional Chinese Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"control group","PLACEBO_COMPARATOR","Acute phase (0-7 days after onset): Normal saline 250 mL, intravenous drip, once daily.\n\nRecovery phase (8-90 days): Placebo capsules (starch) 0.18 g\u002Fcapsule × 2 capsules, orally, three times daily.",[13],"Drug: corresponding control group sequential intervention",{"label":15,"type":16,"description":17,"interventionNames":18},"treatment group","EXPERIMENTAL","Trial group:\n\nAcute phase (0-7 days after onset): Breviscapine injection 40 mL diluted with 250 mL normal saline, intravenous drip, once daily.\n\nRecovery phase (8-90 days): Dengzhan Shengmai capsules 0.18 g\u002Fcapsule × 2 capsules, orally, three times daily.",[19],"Drug: Dengzhan Shengmai - Erigeron breviscapus sequential intervention",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dengzhan Shengmai - Erigeron breviscapus sequential intervention","Trial group:\n\nAcute phase (0-7 days after onset): Breviscapine of Dengzhan Xixin injection 40 mL diluted with 250 mL normal saline, intravenous drip, once daily.\n\nRecovery phase (8-90 days): Dengzhan Shengmai capsules 0.18 g\u002Fcapsule × 2 capsules, orally, three times daily.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"corresponding control group sequential intervention","Control group:\n\nAcute phase (0-7 days after onset): Normal saline 250 mL, intravenous drip, once daily.\n\nRecovery phase (8-90 days): Placebo capsules (starch) 0.18 g\u002Fcapsule × 2 capsules, orally, three times daily.",[9],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Cheng xiao","Senior Research Fellow",[36],{"name":37,"class":6},"Nanfang Hospital, Southern Medical University","100640297","phase-2-spatiotemporal-evolution-of-traditional-chinese-medicine-mechanisms-in-acute-ischemic-stroke-treated-with-dengzhan-xixin-and-dengzhan-shengmai-100640297",false,"NCT07591883","Spatiotemporal Evolution of Traditional Chinese Medicine Mechanisms in Acute Ischemic Stroke Treated With Dengzhan Xixin and Dengzhan Shengmai","STEM-DZ","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke in accordance with the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023\n3. Within 48 hours after the first onset\n4. National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 25 points\n5. Voluntarily signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-stroke modified Rankin Scale (mRS) score ≥ 2\n2. Patients with transient ischemic attack (TIA), complicated with cerebral hemorrhage or subarachnoid hemorrhage\n3. patients with brain tumor, Alzheimer's disease, psychosis, or a confirmed diagnosis of dementia\n4. Patients undergoing endovascular thrombectomy\n5. Patients with severe cardiac diseases such as valvular heart disease, infective endocarditis, myocardial infarction, heart failure, severe hepatic or renal insufficiency, respiratory failure, malignant tumor, or massive gastrointestinal hemorrhage\n6. Patients who have used any preparations containing the same ingredients as the study drug (e.g., Erigeron breviscapus, ginseng, dwarf lilyturf tuber, schisandra chinensis, etc.) within the past 2 weeks\n7. Patients with a history of allergy to the study drug or preparations containing the same ingredients\n8. Pregnant or lactating women\n9. Patients judged by the investigators as unsuitable for participation in this trial.","ALL","18 Years",{"count":48,"type":49},358,"ESTIMATED","INTERVENTIONAL",[52,53],"PHASE2","PHASE3","To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.",[56,57,58],"Ischemic Strokes","Traditional Chinese Medicine (TCM)","Prognosis",[60,57,61,62],"Ischemic Stroke","Dianzhizhengmai Capsules","Dengzhanxixin Injection","NOT_YET_RECRUITING","2026-05-11",{"date":66,"type":67},"2026-05-18","ACTUAL",{"date":69,"type":49},"2026-06-01",{"date":71,"type":49},"2029-07-31",{"name":5,"class":6}]